Get the Stockscreener App
1.16
5.45%
0.06
After Hours:
1.15
-0.01
-0.86%
Immunic Inc stock is traded at $1.16, with a volume of 481.59K.
It is up +5.45% in the last 24 hours and up +23.67% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$1.10
Open:
$1.15
24h Volume:
481.59K
Relative Volume:
0.54
Market Cap:
$104.49M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.5498
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
-0.85%
1M Performance:
+23.67%
6M Performance:
-22.15%
1Y Performance:
-14.71%
1-Day Range:
$1.10
$1.16
1-Week Range:
$1.06
$1.20
52-Week Range:
$0.9204
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.16 | 104.49M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic at Leerink’s Conference: Strategic Moves in MS Treatment - Investing.com
Immunic Therapeutics advances MS Drug , Phase 2 CALLIPER trial readout in April - Proactive financial news
Immunic (IMUX) to Release Quarterly Earnings on Thursday - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Analysts - Defense World
Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data - Proactive Investors
Immunic to Participate in Scientific and Investor Conferences in March - Kilgore News Herald
Immunic announces participation in Hamburg and Miami conferences - Proactive Investors USA
Immunic Showcases Dual-Action Drug Research at Major Virology Meeting While Courting Investors - StockTitan
Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
Biotechs challenge big pharma with new oral weight loss therapies - Proactive Investors USA
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis - The Malaysian Reserve
Immunic to highlight vidofludimus calcium’s potential as MS therapy at upcoming forum - Proactive Investors USA
Immunic (NASDAQ:IMUX) Receives Buy Rating from HC Wainwright - MarketBeat
How Do Things Look For Immunic Inc (NASDAQ: IMUX) In The Short-Term? - Stocks Register
Immunic's (IMUX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
Immunic (IMUX) to Release Earnings on Thursday - MarketBeat
Immunic drug candidate may offer new obesity treatmentICYMI - Proactive Investors USA
Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week - Yahoo Finance
H.C. Wainwright maintains Immunic stock Buy rating, $10 target By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains Immunic stock Buy rating, $10 target - Investing.com
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing - The Malaysian Reserve
Market movers: Walmart, Palantir, Immunic, Alibaba… - Proactive Investors UK
Immunic’s IMU-856 shows promise in weight management By Investing.com - Investing.com Nigeria
Immunic highlights IMU-856’s potential as weight management therapy - Proactive Investors Australia
Immunic's IMU-856 shows promise in weight management - Investing.com
Immunic’s IMU-856 shows promise for obesity treatment - Proactive Investors USA
Immunic's IMU-856 shows promise in weight management By Investing.com - Investing.com South Africa
Immunic announces IMU-856 demonstrated dose-dependent increase - TipRanks
Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1 -February 20, 2025 at 07:31 am EST - Marketscreener.com
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
Pleasing Signs As A Number Of Insiders Buy Immunic Stock - Simply Wall St
Immunic Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Immunic (NASDAQ:IMUX) Downgraded to Sell Rating by StockNews.com - MarketBeat
IMUX stock touches 52-week low at $0.92 amid market challenges - MSN
Breaking Barriers: Immunic CSO marks International Day of Women and Girls in Science - Proactive Investors USA
Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Immunic CEO on key MS trial data coming in April - Proactive Investors USA
Immunic Inc (IMUX) Becoming More Attractive for Investors - Knox Daily
Immunic Inc’s results are impressive - US Post News
Market Recap: Immunic Inc (IMUX)’s Negative Momentum, Closing at 0.95 - The Dwinnex
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in January - MarketBeat
Immunic announces attendance at February investor and scientific conferences - Proactive Investors USA
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):